China's NMPA Approves Phase III Trial of Shanghai RAAS SR604 Injection
China's National Medical Products Administration has approved a Phase III clinical trial of SR604 injection, developed by Shanghai RAAS Blood Products. The approval was recorded in the drug clinical trial registration information on September 16, 2026. No patient enrollment figures, trial sites, or timelines were disclosed in the registration entry.
On September 16, 2026, drug clinical trial registration information from the National Medical Products Administration showed that Phase III clinical trials of SR604 injection, developed by Shanghai RAAS, have been approved.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 50/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.